Navigation Links
IBM Watson Hard At Work: New Breakthroughs Transform Quality Care for Patients
Date:2/8/2013

dent of Memorial Sloan-Kettering Cancer Center. "Ultimately, we expect this comprehensive, evidence-based approach will profoundly enhance cancer care by accelerating the dissemination of practice-changing research at an unprecedented pace."

The Maine Center for Cancer Medicine and WESTMED Medical Group are the first two early adopters of the capability. Their oncologists will begin testing the product and providing feedback to WellPoint, IBM and Memorial Sloan-Kettering to improve usability. 

Speeding Utilization Management to Improve Patient Care
Throughout WellPoint's utilization management pilot, Watson absorbed more than 25,000 test case scenarios and 1,500 real-life cases, and gained the ability to interpret the meaning and analyze queries in the context of complex medical data and human and natural language, including doctors notes, patient records, medical annotations and clinical feedback. In addition, more than 14,700 hours of hands-on training was spent by nurses who meticulously trained Watson.   Watson continues to learn while on the job, much like a medical resident, while working with the WellPoint nurses who originally conducted its training.

Watson started processing common, medical procedure requests by providers for members in WellPoint affiliated health plans in December, and was expanded to include five provider offices in the Midwest.  Watson will serve as a powerful tool to accelerate the review process between a patient's physician and their health plan.

"The health care industry must drive transformation through innovation, including harnessing the latest technology that will ultimately benefit the health care consumer," said Lori Beer , WellPoint's executive vice president of Specialty Businesses and Information Technology. "We believe that WellPoint's data, knowledge and extensive provider network, combined with the IBM Watson technology and Memorial
'/>"/>

SOURCE IBM
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Watson to Host Conference Call and Webcast to Discuss First Quarter 2012 Earnings
2. Watson to Acquire Actavis Group for EUR4.25 Billion
3. Watson Names Lisa DeFrancesco Vice President, Global Investor Relations
4. Watson to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
5. Watson Confirms Lo Loestrin® Fe Patent Challenge
6. Watson to Present at the Sanford C. Bernstein 28th Annual Strategic Decisions Conference
7. Watson Confirms Testim® Patent Challenge
8. Watson to Present at the Jefferies 2012 Global Healthcare Conference
9. Watson Announces Lidoderm® Patent Challenge Settlement
10. Endo Announces Resolution of Patent Litigation with Watson Pharmaceuticals Related to Lidoderm®
11. Watson to Host Second Quarter 2012 Earnings Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Intarcia ... interim clinical data for its lead candidate ITCA 650 ... patients with high baseline HbA1c levels at the 50 ... the Study of Diabetes (EASD). Data from the open-label, ... levels of blood sugar in patients with poorly controlled ...
(Date:9/19/2014)... BALTIMORE and CAMBRIDGE, Mass. ... Diagnostics Inc. (PGDx), a provider of advanced ... Blueprint Medicines , a leader in discovering and ... cancers, today disclosed the first-ever comprehensive genomic study ... and deadly cancer of the female reproductive system, ...
(Date:9/19/2014)... 19, 2014  PCI is pleased to announce ... is a leading provider of Clinical Trial Services ... Wales in the ... expands PCI,s presence in the UK/EU to support ... packaging, storage and distribution capacity, as well as ...
Breaking Medicine Technology:Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6
... April 23, 2007 /PRNewswire-FirstCall/,Micromet, Inc. today announced ... collaboration with MedImmune, Inc. for the development,of ... validated tumor- associated antigen frequently expressed on,various ... 2007 Annual Meeting of the American Association ...
... 23, 2007 - Aeolus,Pharmaceuticals, Inc. (OTCBB:AOLS) announced ... Linda University Medical Center showing,that one of ... an important role regulating the oxidative damage,induced ... alone or in combination with surgery,and chemotherapy ...
Cached Medicine Technology:Micromet Achieves Milestone in BiTE Research Collaboration with,MedImmune 2Micromet Achieves Milestone in BiTE Research Collaboration with,MedImmune 3Micromet Achieves Milestone in BiTE Research Collaboration with,MedImmune 4Aeolus Pharmaceuticals' AEOL 10113 May Play an Important Role,Regulating the Oxidative Damage Induced by Ionizing Radiation 2Aeolus Pharmaceuticals' AEOL 10113 May Play an Important Role,Regulating the Oxidative Damage Induced by Ionizing Radiation 3
(Date:9/19/2014)... 19, 2014 Lipitor lawsuits ( http://www.thelipitorlawsuit.com/ ... patients to develop Type 2 diabetes continue to move ... U.S. District Court, District of South Carolina, Bernstein Liebhard ... September 12, 2014, discovery is underway and moving forward ... that Pfizer, Inc., the manufacturer of Lipitor, has produced ...
(Date:9/19/2014)... 2014 In partnership with Raw Beauty NYC, ... part of the project’s social media efforts. StudioPMG is honored ... re-define the perception of beauty as it applies to disabled ... idea by Shelly Baer and Vanessa Silberman, who wanted to ... and beautiful. Ginny Dixon, Wendy Crawford, Susan Solman and Sabrina ...
(Date:9/19/2014)... Fla. Researchers at Jacksonville,s campus of Mayo Clinic ... they say contributes to both overproduction of toxic protein ... as well as loss of communication between neurons ... Their study, in the online issue of ... specific defect with drugs "may rejuvenate or rescue this ...
(Date:9/19/2014)... states are passing legislation permitting or requiring schools to ... having a severe allergic reaction. Epinephrine auto-injectors are ... can lead to throat swelling, breathing difficulties, a steep ... In people with severe allergies to certain foods, such ... drugs, anaphylaxis can occur within moments of exposure to ...
(Date:9/19/2014)... and large protein complexes are notoriously difficult to study ... very difficult, if not impossible, to crystallize, but also ... The result is that when a structure can be ... reveals a mosaic-like spread of protein domains that sometimes ... Brunger. (2014), Acta Cryst . D70, 2241-2255; ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:OC Healthcare Agency StudioPMG Partners with The Raw Beauty Project ™ NYC 2014 2Health News:Mayo researchers reveal pathway that contributes to Alzheimer's disease 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 3Health News:A refined approach to proteins at low resolution 2Health News:A refined approach to proteins at low resolution 3
... from 12 Days to 27 Hours , ... leading provider of Windows file server virtualization solutions, today ... for medical research and treatment, has deployed its AutoClone(TM) ... of its Windows data replication operations. Since its ...
... line to provide sun protection, laughs and college ... Today non-profit Cancer for College launches a ... All proceeds from the sunscreen sales will go ... in granting college scholarships to cancer survivors and ...
... COM,VANCOUVER, May 19 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: ... period under the Hart-Scott-Rodino Act for the collaboration and ... Merck affiliate for development and commercialization of vernakalant, an ... expired, and the agreement is now effective. , Under ...
... say the disease is no more dangerous than regular ... World Health Organization may declare a full-fledged swine flu ... has swept through Japan, a former WHO infectious disease ... occurring in a region outside North America, where a ...
... plating system offers zero-step locking mechanismHOFFMAN ESTATES, Ill., ... market introduction of the KINETIC-SL Dynamic Anterior Cervical ... from the U.S. Food and Drug Administration (FDA) ... cervical plating system and utilizes a ...
... DIEGO, May 19 /PRNewswire/ -- ... major advances in the development of their first-in-class, CK2 ... Wednesday, May 20th at 4:40 pm. William G. Rice, ... antitumor properties and tumor selectivity of CX-4945, the Company,s ...
Cached Medicine News:Health News:Children's Hospital Boston Deploys AutoVirt Solution to Increase Speed and Efficiency of Windows Data Replication 2Health News:Children's Hospital Boston Deploys AutoVirt Solution to Increase Speed and Efficiency of Windows Data Replication 3Health News:Children's Hospital Boston Deploys AutoVirt Solution to Increase Speed and Efficiency of Windows Data Replication 4Health News:Photos: Will Ferrell Sunscreen to Launch Just in Time for Summer 2Health News:Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective 2Health News:Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective 3Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 2Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 3Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 4Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 5Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 6Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 7Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 8Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 9Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 10Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 11Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 12Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 13Health News:Cylene to Announce New Data on Its First-in-Class Oral CK2 Inhibitor Against Cancer at BIO Conference 2